Fat Content in Liver and Skeletal Muscle Changes in a Reciprocal Manner in Patients with Acromegaly during Combination Therapy with a Somatostatin Analog and a GH Receptor Antagonist: A Randomized Clinical Trial

被引:38
作者
Madsen, Michael [1 ]
Krusenstjerna-Hafstrom, Thomas [2 ]
Moller, Louise [1 ]
Christensen, Britt [1 ]
Vendelbo, Mikkel Holm [1 ]
Pedersen, Steen B. [1 ]
Frystyk, Jan [1 ]
Jessen, Niels [1 ]
Hansen, Troels Krarup [1 ]
Stodkilde-Jorgensen, Hans [3 ]
Flyvbjerg, Allan [1 ]
Jorgensen, Jens Otto L. [1 ]
机构
[1] Aarhus Univ Hosp, Dept Internal Med & Endocrinol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Pediat, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ Hosp, Magnet Resonance Res Ctr, DK-8000 Aarhus C, Denmark
基金
英国医学研究理事会;
关键词
GROWTH-HORMONE DEFICIENCY; INSULIN-RESISTANCE; NONALCOHOLIC STEATOHEPATITIS; RESONANCE SPECTROSCOPY; ECTOPIC FAT; HUMAN SERUM; FACTOR-I; PEGVISOMANT; HEALTHY; GLUCOSE;
D O I
10.1210/jc.2011-2681
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Pegvisomant is a GH antagonist, which is used for the treatment of acromegalic patients. It effectively blocks the hepatic and peripheral effects of GH, but transient elevations in circulating liver enzymes of unknown pathogenesis may occur, which seems to be more prevalent when the treatment is combined with a somatostatin analog (SA). Accumulation of intrahepatic lipid is a known cause of elevated liver enzymes, and there is evidence to suggest that GH impacts lipid content in liver and skeletal muscle. Objective: Our objective was to measure lipid content in liver and skeletal muscle in acromegalic patients before and after cotreatment with pegvisomant and SA as compared with SA monotherapy. Design: Eighteen acromegalic patients well controlled on SA monotherapy were randomized in a parallel study over 24 wk to 1) unchanged SA monotherapy, or 2) cotreatment with pegvisomant (15-30 mg twice a week) and SA (half the usual dosage). Setting: This was an investigator-initiated study in a single tertiary referral center. Main Outcome Measures: Intrahepatic lipid (IHL) and intramyocellular lipid (IMCL) was assessed by H-1 magnetic resonance spectroscopy. Results: IHL increased in the cotreatment group compared with SA only (P = 0.002). The increase was positively correlated to weekly pegvisomant dose (r(2) = 0.52; P = 0.01). By contrast, IMCL decreased in the cotreatment group compared with SA only (P = 0.01). These changes related neither to insulin sensitivity nor inflammatory markers. Conclusion: Cotreatment with pegvisomant and a reduced SA dose increase IHL and decrease IMCL compared with SA monotherapy. The clinical implications remain unclear, but increased IHL may be causally linked to the transient elevations in liver enzymes observed during pegvisomant treatment. (J Clin Endocrinol Metab 97: 1227-1235, 2012)
引用
收藏
页码:1227 / 1235
页数:9
相关论文
共 41 条
[11]  
Frystyk J, 1995, GROWTH REGULAT, V5, P169
[12]   CIDE proteins and metabolic disorders [J].
Gong, Jingyi ;
Sun, Zhiqi ;
Li, Peng .
CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (02) :121-126
[13]   Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency [J].
Ichikawa, T ;
Hamasaki, K ;
Ishikawa, H ;
Ejima, E ;
Eguchi, K ;
Nakao, K .
GUT, 2003, 52 (06) :914-914
[14]   Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease [J].
Ichikawa, Tatsuki ;
Nakao, Kazuhiko ;
Hamasaki, Keisuke ;
Furukawa, Ryuji ;
Tsuruta, Shotarou ;
Ueda, Yasuo ;
Taura, Naota ;
Shibata, Hidetaka ;
Fujimoto, Masumi ;
Toriyama, Kan ;
Eguchi, Katsumi .
HEPATOLOGY INTERNATIONAL, 2007, 1 (02) :287-294
[15]   Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist [J].
Jorgensen, JOL ;
Feldt-Rasmussen, U ;
Frystyk, J ;
Chen, JW ;
Kristensen, LO ;
Hagen, C ;
Orskov, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5627-5631
[16]   Adiponectin Oligomers and Ectopic Fat in Liver and Skeletal Muscle in Humans [J].
Kantartzis, Konstantinos ;
Staiger, Harald ;
Machann, Juergen ;
Schick, Fritz ;
Claussen, Claus D. ;
Machicao, Fausto ;
Fritsche, Andreas ;
Haering, Hans-Ulrich ;
Stefan, Norbert .
OBESITY, 2009, 17 (02) :390-392
[17]   Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics [J].
Krag, Morten B. ;
Gormsen, Lars C. ;
Guo, ZengKui ;
Christiansen, Jens S. ;
Jensen, Michael D. ;
Nielsen, Soren ;
Jorgensen, Jens O. L. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 292 (03) :E920-E927
[18]   The role of lipid accumulation in liver and muscle for insulin resistance and type 2 diabetes mellitus in humans [J].
Krssak, M ;
Roden, M .
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2004, 5 (02) :127-134
[19]   Effect of insulin therapy on coagulation and fibrinolysis in medical intensive care patients [J].
Langouche, Lies ;
Meersseman, Wouter ;
Perre, Sarah Vander ;
Milants, Ilse ;
Wouters, Pieter J. ;
Hermans, Greet ;
Gjedsted, Jakob ;
Hansen, Troels K. ;
Amout, Jozef ;
Wilmer, Alexander ;
Schetz, Miet ;
Van den Berghe, Greet .
CRITICAL CARE MEDICINE, 2008, 36 (05) :1475-1480
[20]   Ectopic Fat and Insulin Resistance [J].
Lettner, Angelika ;
Roden, Michael .
CURRENT DIABETES REPORTS, 2008, 8 (03) :185-191